Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says

12:18 PM EST, 11/05/2026 (MT Newswires) -- Cytokinetics' (CYTK) Myqorzo could inflect revenue in 2027 and beyond given its positive launch trajectory and potential label expansion, RBC Capital Markets said in a note Wednesday. Myqorzo was launched in the US in January following FDA approval to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. Myqorzo's $43.1 million Q3 revenue in the US indicate that it is set to outpace its rival therapy Camzyos, with steady patient additions that boost market share, according to the note. RBC estimates Myqorzo's US revenue reaching $500 million in 2027, building to a revenue opportunity of about $5 billion by 2035. International growth could take longer amid pending approvals and launches in other markets, the investment firm said. The firm also noted Myqorzo's potential label expansion to include non-obstructive hypertrophic cardiomyopathy, possibly adding more than $1.1 billion in revenue by 2035. RBC Capital Markets has an outperform rating on Cytokinetics, with a $113 price target. Shares of Cytokinetics were down more than 13% in Thursday trading. Price: 55.25, Change: -8.35, Percent Change: -13.13